BeOne Medicines (NASDAQ:ONC) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of BeOne Medicines (NASDAQ:ONC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

ONC has been the topic of a number of other reports. Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Leerink Partners lifted their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $390.92.

BeOne Medicines Trading Down 1.7%

Shares of ONC stock opened at $312.02 on Friday. BeOne Medicines has a 1 year low of $253.95 and a 1 year high of $385.22. The firm has a market capitalization of $34.23 billion, a PE ratio of 69.80 and a beta of 0.49. The stock has a fifty day moving average of $290.21 and a two-hundred day moving average of $308.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. As a group, research analysts expect that BeOne Medicines will post 5.86 EPS for the current year.

Insider Buying and Selling at BeOne Medicines

In other news, CEO John Oyler sold 145,861 shares of the company’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the sale, the chief executive officer directly owned 8,122 shares in the company, valued at approximately $2,484,925.90. This represents a 94.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lai Wang sold 1,068 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $276.74, for a total value of $295,558.32. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 233,647 shares of company stock worth $70,335,553 over the last three months. 6.19% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in shares of BeOne Medicines by 100.6% during the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the period. Capital International Sarl increased its stake in shares of BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after acquiring an additional 3,956 shares during the last quarter. Slow Capital Inc. raised its holdings in BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after purchasing an additional 9,280 shares during the period. Capital International Investors raised its stake in BeOne Medicines by 1.3% during the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after buying an additional 67,808 shares during the period. Finally, UBS Group AG raised its position in shares of BeOne Medicines by 45.0% during the fourth quarter. UBS Group AG now owns 152,087 shares of the company’s stock worth $46,206,000 after purchasing an additional 47,172 shares during the period. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.